Breast Cancer Female Clinical Trial
— BCIOfficial title:
The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy: A Randomized, Sham-Controlled Trial
Verified date | May 2024 |
Source | The University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study is a randomized, parallel-group, placebo-controlled, subject- and assessor-blind trial. It is designed according to CONSORT and STRICTA recommendations. The 138 subjects will be randomly assigned to one of the two arms using block randomization in a 1:1 ratio: (I) acupuncture treatment, and (II) sham treatment. In groups (I) and (II), acupuncture or sham acupuncture treatment will be given twice a week for 6 weeks (12 sessions). A maintenance tapering treatment schedule will then be applied once per month for 3 months (3 sessions). The primary outcome will be improvement in sleep quality as measured by the change of ISI after 6 weeks of treatment. Secondary outcome assessment tools will include PSQI, HADS, BPI, BFI, FACT-B, sleep diaries, drug diaries, blinding success questionnaire and reports of adverse events. The subjects will be scheduled for on-site follow-up assessments at 3 and 6 months after the last treatment. An intention to treat (ITT) approach will be used for data analysis.
Status | Completed |
Enrollment | 138 |
Est. completion date | July 30, 2022 |
Est. primary completion date | January 30, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Female patients between 18 and 75 years of age. - Diagnosis of stage (American Joint Committee on Cancer (AJCC) TNM) I-IV breast cancer. - Currently receiving chemotherapy, or have completed chemotherapy no more than 6 months. - Insomnia onset after the diagnosis of breast cancer. - Insomnia occurs at least 3 nights per week, and presents for at least 1 month, with fulfilment of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for brief insomnia disorder Insomnia severity as defined by an ISI score of no less than 10 in the past 2 weeks. - Expected survival time of more than 6 months. - Ability to understand the nature of the study and willingness to give informed consent. - Ability to provide responses during outcome measurement. Exclusion Criteria: - Other sleep disorder (e.g., obstructive sleep apnoea). - Shift work or irregular sleep pattern. - Severe visual, hearing or language defects. - Severe hematological dysfunction (platelet count <60,000/µL, haemoglobin <8 g/dL or absolute neutrophil count <1000/µL). - History of acupuncture use in the previous 3 months. - Participation in other clinical trials with intervention within 3 months of the beginning of the trial. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Department of Clinical Oncology, Queen Mary Hospital | Hong Kong | |
Hong Kong | Hong Kong Sanatorium & Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey SG, Badros AZ. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther. 2014 Sep;13(5):396-404. doi: 10.1177/1534735414534729. Epub 2014 May 26. — View Citation
Bergdahl L, Broman JE, Berman AH, Haglund K, von Knorring L, Markstrom A. Sleep patterns in a randomized controlled trial of auricular acupuncture and cognitive behavioral therapy for insomnia. Complement Ther Clin Pract. 2017 Aug;28:220-226. doi: 10.1016/j.ctcp.2017.06.006. Epub 2017 Jun 30. — View Citation
Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmaro LA, Tillie JM, Dhabhar FS. Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun. 2015 Aug;48:102-14. doi: 10.1016/j.bbi.2015.02.017. Epub 2015 Feb 26. — View Citation
Dahiya S, Ahluwalia MS, Walia HK. Sleep disturbances in cancer patients: underrecognized and undertreated. Cleve Clin J Med. 2013 Nov;80(11):722-32. doi: 10.3949/ccjm.80a.12170. — View Citation
Fakih R, Rahal M, Hilal L, Hamieh L, Dany M, Karam S, Shehab L, El Saghir NS, Tfayli A, Salem Z, Assi H, Temraz S, Shamseddine A, Mukherji D. Prevalence and Severity of Sleep Disturbances among Patients with Early Breast Cancer. Indian J Palliat Care. 2018 Jan-Mar;24(1):35-38. doi: 10.4103/IJPC.IJPC_137_17. — View Citation
Garland SN, Gehrman P, Barg FK, Xie SX, Mao JJ. CHoosing Options for Insomnia in Cancer Effectively (CHOICE): Design of a patient centered comparative effectiveness trial of acupuncture and cognitive behavior therapy for insomnia. Contemp Clin Trials. 2016 Mar;47:349-55. doi: 10.1016/j.cct.2016.02.010. Epub 2016 Mar 5. — View Citation
Krystal AD. The changing perspective on chronic insomnia management. J Clin Psychiatry. 2004;65 Suppl 8:20-5. — View Citation
Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, Fielding R, Yip PS, Lau EM, Wong CM. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer. 2002 Oct 21;87(9):982-8. doi: 10.1038/sj.bjc.6600583. Erratum In: Br J Cancer. 2003 Jun 16;88(12):2006. — View Citation
Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011 May 1;34(5):601-8. doi: 10.1093/sleep/34.5.601. — View Citation
Savard J, Ivers H, Savard MH, Morin CM. Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study. Cancer. 2015 May 15;121(10):1703-11. doi: 10.1002/cncr.29244. Epub 2015 Feb 11. — View Citation
Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol. 2011 Sep 10;29(26):3580-6. doi: 10.1200/JCO.2010.33.2247. Epub 2011 Aug 8. — View Citation
Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001 Feb 1;19(3):895-908. doi: 10.1200/JCO.2001.19.3.895. — View Citation
Savard J, Villa J, Ivers H, Simard S, Morin CM. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol. 2009 Nov 1;27(31):5233-9. doi: 10.1200/JCO.2008.21.6333. Epub 2009 Sep 8. — View Citation
Savard MH, Savard J, Simard S, Ivers H. Empirical validation of the Insomnia Severity Index in cancer patients. Psychooncology. 2005 Jun;14(6):429-41. doi: 10.1002/pon.860. — View Citation
Streitberger K, Kleinhenz J. Introducing a placebo needle into acupuncture research. Lancet. 1998 Aug 1;352(9125):364-5. doi: 10.1016/S0140-6736(97)10471-8. — View Citation
Suen LK, Wong TK, Leung AW. Effectiveness of auricular therapy on sleep promotion in the elderly. Am J Chin Med. 2002;30(4):429-49. doi: 10.1142/S0192415X0200051X. — View Citation
Yeung WF, Chung KF, Leung YK, Zhang SP, Law AC. Traditional needle acupuncture treatment for insomnia: a systematic review of randomized controlled trials. Sleep Med. 2009 Aug;10(7):694-704. doi: 10.1016/j.sleep.2008.08.012. Epub 2009 Mar 19. — View Citation
Yeung WF, Chung KF, Zhang SP, Yap TG, Law AC. Electroacupuncture for primary insomnia: a randomized controlled trial. Sleep. 2009 Aug;32(8):1039-47. doi: 10.1093/sleep/32.8.1039. — View Citation
Yin X, Gou M, Xu J, Dong B, Yin P, Masquelin F, Wu J, Lao L, Xu S. Efficacy and safety of acupuncture treatment on primary insomnia: a randomized controlled trial. Sleep Med. 2017 Sep;37:193-200. doi: 10.1016/j.sleep.2017.02.012. Epub 2017 Mar 8. — View Citation
Zia FZ, Olaku O, Bao T, Berger A, Deng G, Fan AY, Garcia MK, Herman PM, Kaptchuk TJ, Ladas EJ, Langevin HM, Lao L, Lu W, Napadow V, Niemtzow RC, Vickers AJ, Shelley Wang X, Witt CM, Mao JJ. The National Cancer Institute's Conference on Acupuncture for Symptom Management in Oncology: State of the Science, Evidence, and Research Gaps. J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52):lgx005. doi: 10.1093/jncimonographs/lgx005. — View Citation
Zou C, Yang L, Wu Y, Su G, Chen S, Guo X, Wu X, Liu X, Lin Q. Auricular acupressure on specific points for hemodialysis patients with insomnia: a pilot randomized controlled trial. PLoS One. 2015 Apr 15;10(4):e0122724. doi: 10.1371/journal.pone.0122724. eCollection 2015. — View Citation
* Note: There are 21 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insomnia Severity Index (ISI) | The primary outcome will be the change of ISI score between the baseline and the end of the 6-week treatment. The ISI is a seven-item questionnaire devised to diagnose and assess the severity of insomnia. | Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. | |
Secondary | Actiwatch | The subjects will wear Actiwatch for 1 week at baseline period and the end of 6-week treatment. | Baseline, 6 week. | |
Secondary | Sleep diary | Subjects will be given daily sleep diary for 1 week at baseline period and the end of 6-week treatment. | Baseline, 6 week. | |
Secondary | Pittsburgh Sleep Quality Index (PSQI) | The PSQI is a reliable and valid self-reported questionnaire that assesses sleep quality over 1 month. | Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | The HADS, a 14-item self-rated questionnaire, evaluates the severity of depressive and anxiety symptoms. | Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. | |
Secondary | Brief Pain Inventory-Short Form (BPI-SF) | The BFI is a brief screening tool designed to assess the severity and impact of cancer-related fatigue on daily functioning. | Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. | |
Secondary | Brief Fatigue Inventory (BPI) | The BPI is a self-administered questionnaire designed to assess cancer pain. | Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. | |
Secondary | Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) | The FACT-B is a patient-reported outcome measure used to assess health-related quality of life in breast cancer patients. | Baseline, 3 week, 6 week, 10 week, 14 week, 18 week, 30 week, 42 week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03080623 -
Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
|
||
Completed |
NCT05527769 -
Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
|
||
Completed |
NCT06376578 -
Exercise Interventions for Improving Health in Breast Cancer Survivors
|
N/A | |
Completed |
NCT03004534 -
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
|
Early Phase 1 | |
Recruiting |
NCT05020574 -
Microbiome and Association With Implant Infections
|
Phase 2 | |
Active, not recruiting |
NCT06277141 -
The Vitality Mammography Messaging Study
|
N/A | |
Completed |
NCT03555227 -
USG PECS vs LIA for Breast Cancer Surgery
|
N/A | |
Completed |
NCT03270111 -
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
|
N/A | |
Active, not recruiting |
NCT03917082 -
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05561842 -
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
|
||
Completed |
NCT04554056 -
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03127995 -
Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence
|
N/A | |
Active, not recruiting |
NCT02237469 -
Prone Breast Radiotherapy Treatment Planning Observational Study
|
||
Completed |
NCT01204125 -
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04565054 -
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
|
Phase 3 | |
Not yet recruiting |
NCT06412133 -
Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients
|
N/A | |
Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
Recruiting |
NCT06087120 -
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
|
||
Recruiting |
NCT06058936 -
Exercises Using Virtual Reality on Cancer Patients
|
N/A | |
Completed |
NCT03470935 -
Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger
|